Literature DB >> 2160427

Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides.

S Head1, K Ramotar, C Lingwood.   

Abstract

Polymyxin B, an amphipathic cyclic decapeptide produced by Bacillus polymyxa, is routinely used in the extraction of the components from the periplasmic space of gram-negative bacteria. Vero cytotoxin 1 (VT1) is an Escherichia coli-elaborated subunit toxin which binds to the glycolipid globotriosylceramide (Gal-alpha 1-4-Gal beta 1-4-Glc-ceramide [Gb3]) and has been strongly implicated in the etiology of the hemolytic uremic syndrome and hemorrhagic colitis. We now show by in vitro glycolipid-binding assays that in the presence of low concentrations of polymyxin B, globotetraosylceramide (GalNAc beta 1-3Gal alpha 1-4Gal beta 1-4Glc-ceramide [Gb4]) is also recognized by both the VT1 B (binding) subunit and holotoxin. Melittin, a 26-amino-acid cyclic peptide of similar amphipathic nature, produced the same effect, whereas a hydrophobic blocking agent did not. Triton X-100 did not increase binding of VT1 to Gb4 but prevented glycolipid binding in toto at concentrations above 0.5%. Caution is therefore advised in the analysis of VT1 glycolipid binding in the presence of amphipathic peptides.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160427      PMCID: PMC258668          DOI: 10.1128/iai.58.6.1532-1537.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Antigenic heterogeneity of Escherichia coli verotoxins.

Authors:  M A Karmali; M Petric; S Louie; R Cheung
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

2.  Two distinct toxins active on Vero cells from Escherichia coli O157.

Authors:  S M Scotland; H R Smith; B Rowe
Journal:  Lancet       Date:  1985-10-19       Impact factor: 79.321

3.  Cloning of genes determining the production of vero cytotoxin by Escherichia coli.

Authors:  G A Willshaw; H R Smith; S M Scotland; B Rowe
Journal:  J Gen Microbiol       Date:  1985-11

4.  Cloning and expression of the genes specifying Shiga-like toxin production in Escherichia coli H19.

Authors:  A Huang; S de Grandis; J Friesen; M Karmali; M Petric; R Congi; J L Brunton
Journal:  J Bacteriol       Date:  1986-05       Impact factor: 3.490

5.  Sensitive method for detecting low numbers of verotoxin-producing Escherichia coli in mixed cultures by use of colony sweeps and polymyxin extraction of verotoxin.

Authors:  M A Karmali; M Petric; C Lim; R Cheung; G S Arbus
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

6.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

7.  Interaction of glycosphingolipids with melittin and myelin basis protein in monolayers.

Authors:  G D Fidelio; B Maggio; F A Cumar; R Caputto
Journal:  Biochem J       Date:  1981-02-01       Impact factor: 3.857

8.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

9.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

10.  Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

Authors:  M Jacewicz; H Clausen; E Nudelman; A Donohue-Rolfe; G T Keusch
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  4 in total

1.  Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro.

Authors:  M Bitzan; S Richardson; C Huang; B Boyd; M Petric; M A Karmali
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

2.  Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit.

Authors:  G J Tyrrell; K Ramotar; B Toye; B Boyd; C A Lingwood; J L Brunton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

3.  Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes.

Authors:  S Arab; C A Lingwood
Journal:  Glycoconj J       Date:  1996-04       Impact factor: 2.916

4.  Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs.

Authors:  B Boyd; G Tyrrell; M Maloney; C Gyles; J Brunton; C Lingwood
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.